Literature DB >> 28341560

Showcasing Clinical Development and Production of Cellular Therapies.

Bruce L Levine1, Andrew D Fesnak2, Isabelle Riviere3.   

Abstract

Mesh：

Year:  2017        PMID： 28341560      PMCID： PMC5383642          DOI： 10.1016/j.ymthe.2017.03.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2016-06       Impact factor: 11.454

Review 2.  Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

Authors:  Xiuyan Wang; Isabelle Rivière
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

Review 3.  Dendritic Cell Therapies for Hematologic Malignancies.

Authors:  Matthew Weinstock; Jacalyn Rosenblatt; David Avigan
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

Review 4.  Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine.

Authors:  Kaoru Mitsui; Kanako Ide; Tomoyuki Takahashi; Ken-Ichiro Kosai
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

Review 5.  Global Manufacturing of CAR T Cell Therapy.

Authors:  Bruce L Levine; James Miskin; Keith Wonnacott; Christopher Keir
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-31       Impact factor: 6.698

Review 6.  Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies.

Authors:  Stefan Irion; Susan E Zabierowski; Mark J Tomishima
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-24       Impact factor: 6.698
  6 in total
  1 in total

Review 1.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.